The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load

AIDS

Volumn 14, Issue 14, 2000, Pages 2129-2136

  Miller, Veronica ^a   Sabin, Caroline A ^b   Phillips, Andrew N ^b   Rottmann, Carsten ^a   Rabenau, Holger ^a   Weidmann, Eckard ^a   Rickerts, Volker ^a   Findhammer, Stephan ^a   Helm, Eilke B ^a   Staszewski, Schlomo ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; VIRUS LOAD;

EID: 0033790674     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200009290-00009     Document Type: Article

References (35)

1. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection
2. HIV-1 RNA levels and the development of clinical disease
3. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure
4. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team
5. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy
6. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
7. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
8. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
9. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for the HIV-infected patients: The INCAS Trial
10. Predictors of a viral response and subsequent virological failure in patients with HIV starting a protease inhibitor
11. Virological response to protease inhibitor therapy in an HIV clinic cohort
12. Evolution of drug resistance associated with loss of viral suppression in patients treated with indinavir, lamivudine and zidovudine
13. Resistance during early virological rebound on amprenavir plus zidovudine plus lamivudine triple therapy or amprenavir monotherapy in ACTG protocol 347
14. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART)
15. Rebound of HIV-1 viral load after suppression to very low levels
16. 1993 Revised classification system for HIV infection and expanded case definition for AIDS among adolescents and adults
17. HIV-1 RNA, CD4 cell count and the risk of progression to AIDS and death during treatment with HIV-1 reverse transcriptase inhibitors
18. Changing patterns of mortality across Europe in patients infected with HIV
19. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
20. Relationship between CD4 lymphocyte nadir, antiretroviral therapy and HIV-I disease progression: Results from the EuroSIDA study
21. Risk of new AIDS diseases in people on triple therapy
22. Host cell-dependent replication efficacy of 3TC-resistant HIV-1 variants
23. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients
24. Impaired fitness of human immunodeficiency virus type I variants with high-level resistance to protease inhibitors
25. Baseline resistance and virological response to Mega-HAART salvage therapies
26. Specific recognition of 3TC-resistant HIV-1 variants by cytotoxic T-cells. [Proceedings of the Fourth International Congress on Drug Therapy in HIV Infection
27. Rapid, transient changes at the env locus of plasma human immunodeficiency virus type I populations during the emergence of protease inhibitor resistance
28. Prediction of human immunodeficiency virus protease cleavage sites in proteins
29. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses
30. In vitro and in vivo anticandidal activity of human immunodeficiency virus ptotease inhibitors
31. Effects of human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients